141 related articles for article (PubMed ID: 27391144)
1. Intratumoral expression of cyclooxygenase-2 (COX-2) is a negative prognostic marker for patients with cutaneous melanoma.
Kuźbicki Ł; Lange D; Stanek-Widera A; Chwirot BW
Melanoma Res; 2016 Oct; 26(5):448-56. PubMed ID: 27391144
[TBL] [Abstract][Full Text] [Related]
2. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
Kuźbicki L; Sarnecka A; Chwirot BW
Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
[TBL] [Abstract][Full Text] [Related]
3. Conjunctival melanoma: association of cyclooxygenase-2 tumor expression to prognosis.
Pinto-Proença R; Santos M; Fonseca C; Fernandes J; Gaspar MF; Proença R
Graefes Arch Clin Exp Ophthalmol; 2018 May; 256(5):989-995. PubMed ID: 29297092
[TBL] [Abstract][Full Text] [Related]
4. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
Chwirot BW; Kuźbicki Ł
Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
[TBL] [Abstract][Full Text] [Related]
5. Prognostic significance of ALCAM (CD166/MEMD) expression in cutaneous melanoma patients.
Donizy P; Zietek M; Halon A; Leskiewicz M; Kozyra C; Matkowski R
Diagn Pathol; 2015 Jul; 10():86. PubMed ID: 26134500
[TBL] [Abstract][Full Text] [Related]
6. Enhanced intratumoral expression of RNF2 is a favorable prognostic factor for patients with cutaneous melanoma?
Kuźbicki Ł; Lange D; Stanek-Widera A; Glińska A; Chwirot BW
Oncotarget; 2018 Apr; 9(25):17656-17663. PubMed ID: 29707138
[TBL] [Abstract][Full Text] [Related]
7. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease.
Thies A; Moll I; Berger J; Wagener C; Brümmer J; Schulze HJ; Brunner G; Schumacher U
J Clin Oncol; 2002 May; 20(10):2530-6. PubMed ID: 12011132
[TBL] [Abstract][Full Text] [Related]
8. CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors.
Monteagudo C; Martin JM; Jorda E; Llombart-Bosch A
J Clin Pathol; 2007 Jun; 60(6):596-9. PubMed ID: 16522748
[TBL] [Abstract][Full Text] [Related]
9. The value of cyclooxygenase-2 expression in differentiating between early melanomas and histopathologically difficult types of benign human skin lesions.
Kuźbicki Ł; Lange D; Strączyńska-Niemiec A; Chwirot BW
Melanoma Res; 2012 Feb; 22(1):70-6. PubMed ID: 22228276
[TBL] [Abstract][Full Text] [Related]
10. Expression of gp100, MART-1, tyrosinase, and S100 in paraffin-embedded primary melanomas and locoregional, lymph node, and visceral metastases: implications for diagnosis and immunotherapy. A study conducted by the EORTC Melanoma Cooperative Group.
de Vries TJ; Smeets M; de Graaf R; Hou-Jensen K; Bröcker EB; Renard N; Eggermont AM; van Muijen GN; Ruiter DJ
J Pathol; 2001 Jan; 193(1):13-20. PubMed ID: 11169510
[TBL] [Abstract][Full Text] [Related]
11. Significance of Vascular Endothelial Growth Factor (VEGF)-C and VEGF-D in the Progression of Cutaneous Melanoma.
Špirić Z; Eri Ž; Erić M
Int J Surg Pathol; 2015 Dec; 23(8):629-37. PubMed ID: 25911567
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
Soares CD; Borges CF; Sena-Filho M; Almeida OP; Stelini RF; Cintra ML; Graner E; Zecchin KG; Jorge J
Melanoma Res; 2017 Oct; 27(5):448-456. PubMed ID: 28604419
[TBL] [Abstract][Full Text] [Related]
13. Prognostic value of galectin-3 in primary cutaneous melanoma.
Buljan M; Šitum M; Tomas D; Milošević M; Krušlin B
J Eur Acad Dermatol Venereol; 2011 Oct; 25(10):1174-81. PubMed ID: 21175876
[TBL] [Abstract][Full Text] [Related]
14. Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma.
Garbe C; Hauschild A; Volkenandt M; Schadendorf D; Stolz W; Reinhold U; Kortmann RD; Kettelhack C; Frerich B; Keilholz U; Dummer R; Sebastian G; Tilgen W; Schuler G; Mackensen A; Kaufmann R
Melanoma Res; 2007 Dec; 17(6):393-9. PubMed ID: 17992123
[TBL] [Abstract][Full Text] [Related]
15. Prognostic importance of the mitotic marker phosphohistone H3 in cutaneous nodular melanoma.
Ladstein RG; Bachmann IM; Straume O; Akslen LA
J Invest Dermatol; 2012 Apr; 132(4):1247-52. PubMed ID: 22297638
[TBL] [Abstract][Full Text] [Related]
16. Microphthalmia transcription factor in malignant melanoma predicts occult sentinel lymph node metastases and survival.
Naffouje S; Naffouje R; Bhagwandin S; Salti GI
Melanoma Res; 2015 Dec; 25(6):496-502. PubMed ID: 26317170
[TBL] [Abstract][Full Text] [Related]
17. c-myc is not useful as prognostic immunohistochemical marker in cutaneous melanoma.
Böni R; Bantschapp O; Müller B; Burg G
Dermatology; 1998; 196(3):288-91. PubMed ID: 9621133
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of neuropilin 1 in melanoma progression and its prognostic significance in patients with melanoma.
Lu J; Cheng Y; Zhang G; Tang Y; Dong Z; McElwee KJ; Li G
Mol Med Rep; 2015 Aug; 12(2):2668-76. PubMed ID: 25954957
[TBL] [Abstract][Full Text] [Related]
19. COX-2 expression in malignant melanoma: a novel prognostic marker?
Becker MR; Siegelin MD; Rompel R; Enk AH; Gaiser T
Melanoma Res; 2009 Feb; 19(1):8-16. PubMed ID: 19430402
[TBL] [Abstract][Full Text] [Related]
20. Expression of thymidine phosphorylase and cyclooxygenase-2 in melanoma.
Minisini AM; Pascoletti G; Intersimone D; Poletto E; Driol P; Spizzo R; Scott CA; Puglisi F; Fasola G; Di Loreto C
Melanoma Res; 2013 Apr; 23(2):96-101. PubMed ID: 23411479
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
